Generic antiepileptic drugs

Current Treatment Options in Neurology

Volumn 10, Issue 4, 2008, Pages 260-268

  Shaw, Susan J ^a   Krauss, Gregory L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CITALOPRAM; CLOBAZAM; DRUG METABOLITE; ETHOSUXIMIDE; ETIRACETAM; FLUOXETINE; FOSPHENYTOIN SODIUM; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PRODRUG; SIMVASTATIN; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZONEGRAM; ZONISAMIDE;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COORDINATION DISORDER; DIZZINESS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SAFETY; DRUG SOLUBILITY; ELDERLY CARE; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; REVIEW; SINGLE DRUG DOSE; SOMNOLENCE;

EID: 58649107320     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-008-0029-6     Document Type: Review

References (35)

1. O'Brien TJ, Cascino GD, So EL, Hann DR: Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology 1998, 51:1034-1039.
2. Lesser RP, Krauss G: Buy some today: Can generics be safely substituted for brand-name drugs? Neurology 2001, 57:571-573.
3. Bialer M: Generic products of antiepileptic drugs (AEDs): Is it an issue? Epilepsia 2007, 48:1825-1832.
4. Liow K, Barkley GL, Pollard JR, et al.: Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007, 68:1249-1250.
5. US Food and Drug Administration (CDER): Office of Generic Drugs - What are generic drugs? http://www.fda.gov/cder/ogd/index.htm#introduction. Accessed December 12, 2007.
6. Castle S, Kanter J: European antitrust regulators raid large drug makers. New York Times. January 17, 2008. http://www.nytimes.com/2008/01/ 17/business/worldbusiness/17compete.html?_r= 2&sq=genericdrugs. Accessed March 19, 2008.
7. Teva Announces Settlement Of Lamictal Litigation With GlaxoSmithKline [press release]. Jerusalem, Israel: Teva Pharmaceutical Industries Ltd; 2005. http://www.tevapharm.com/pr/2005/pr_513.asp. Accessed January 31, 2008.
8. US Food and Drug Administration (CDER): Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. http://www.fda.gov/cder/ob/default.htm. Accessed January 31, 2008.
9. US Food aQd Drug Administration (CDER): Generic drugs: questions and answers. http://www.fda.gov/cder/consumerinfo/generics_q&a.htm. Accessed December 12, 2007.
10. Niazi SK: Handbook of bioequivalence testing. New York: Informa Healthcare USA; 2007: 1-44.
11. Hauser WA, Annegers JF, Rocca WA: Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 1996, 71:576-586.
12. Gidal BE: Antiepileptic drug formulation and treatment in the elderly: biopharmaceutical considerations. Int Rev Neurobiol 2007, 81:299-311.
13. Cloyd JC, Marino S, Birnbaum AK: Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. Int Rev Neurobiol 2007, 81:201-210.
14. Collins NS, Shapiro RA, Ramsay RE: Elders with epilepsy. Med Clin North Am 2006, 90:945-966.
15. Oles KS, Penry JK, Smith LD, et al.: Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 1992, 42:1147-1153.
16. Silpakit O, Amornpichetkoon M, Kaojarern S: Comparative study of bioavailability and clinical efficacy of carbamaze pine in epileptic patients. Ann Pharmacother 1997, 31:548-552.
17. Wilder BJ, Leppik I, Hietpas TJ, et al.: Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. Neurology 2001, 57:582-589.
18. Wilner AN: Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 2004, 5:995-998.
19. US Food and Drug Administration (CDER): Therapeutic equivalence of generic drugs: Response to National Association of Boards of Pharmacy: Immediate release solid oral dosage forms: Scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. http://www.fda.gov/ cder/guidance/cmc5.pdf. Accessed March 19, 2008.
20. Perucca E: Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 2001, 15:405-417.
21. Benet LZ: Why highly variable drugs are safer. Presentation to the FDA Advisory Committee for Pharmaceutical Science; October 6, 2007; Rockville, MD. www.fda.gov/ohrms/dockets/ac/06/slides/2006-4241s2_2.ppt. Accessed March 19, 2008.
22. Oxcarbazepine [package insert]. East Hanover, NJ: Novartis Pharmaceuticals: 2007.
23. Williams RL, for Center for Drug Evaluation and Research: Therapeutic equivalence of generic drugs: Response to National Association of Boards of Pharmacy, April 16, 1997. http://www.fda.gov/cder/news/ntiletter.htm. Accessed March 19, 2008.
24. Hauck WW, Anderson S: Measuring switchability and prescribability: When is average bioequivalence sufficient? J Pharmacokinet Biopharm 1994, 22:551-564.
25. Miller AD, Krauss GL, Hamzeh FM: Improved CNS tolerability following conversion from immediate-to extended-release carbamazepine. Acta Neurol Scand 2004, 109:374-377.
26. Nightingale SL for Center for Drug Evaluation and Research: Therapeutic equivalence of generic drugs: Letter to health practitioners, January 28, 1998. http://www.fda.gov/cder/news/nightgenlett.htm. Accessed March 19, 2008.
27. Mikati M, Bassett N, Schacter S: Double-blind randomized study comparing brand-name and generic phenytoin monotherapy. Epilepsia 1992, 33:359-365.
28. Makus KG, McCormick J: Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther 2007, 29:334-341.
29. Burkhardt RT, Leppik IE, Blesi I, et al.: Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 2004, 63:1494-1496.
30. Andermann F, Duh MS, Gosselin A, Paradis PE: Compulsory generic switching of antiepileptic drugs: High switchback rates to branded compounds compared with other drug classes. Epilepsia 2007, 48:464-469.
31. Aldenkamp AP, Rentmeester T, Hulsman J, et al.: Pharma co kinetics and cognitive effects of carbamazepine formulations with different dissolution rates. Eur J Clin Pharmacol 1998, 54:185-192.
32. Perucca E, Albani F, Capovilla G, et al.: Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 2006, 47:16-20.
33. Kwan P, Brodie MJ: Effectiveness of the first antiepileptic drug. Epilepsia 2001, 42:1255-1260.
34. Hartley R, Aleksandrowicz J, Ng PC, et al.: Breakthrough seizures with generic carbamazepine: A consequence of poorer bioavailability? Br J Clin Pharmacol 1990, 44:227-270.
35. Berg MJ: What's the problem with generic antiepileptic drugs? A call to action. Neurology 2007, 68:1245-1246.